Zobrazeno 1 - 10
of 67
pro vyhledávání: '"Christopher J, LaRocca"'
Autor:
Sacha Robert, Natasha Ivelisse Roman Ortiz, Christopher J. LaRocca, Julie Hanson Ostrander, Julia Davydova
Publikováno v:
Viruses, Vol 16, Iss 4, p 567 (2024)
Adjuvant systemic therapies effectively reduce the risk of breast cancer recurrence and metastasis, but therapy resistance can develop in some patients due to breast cancer stem cells (BCSCs). Oncolytic adenovirus (OAd) represents a promising therape
Externí odkaz:
https://doaj.org/article/e248c0f1cfbc42688c816e365679f650
Publikováno v:
Molecular Therapy: Oncolytics, Vol 28, Iss , Pp 44-45 (2023)
Externí odkaz:
https://doaj.org/article/bb7fe7521be34f138c0e96575ded8002
Autor:
Christopher J. LaRocca, Kari L. Jacobsen, Kazuho Inoko, Stanislav O. Zakharkin, Masato Yamamoto, Julia Davydova
Publikováno v:
Viruses, Vol 15, Iss 7, p 1495 (2023)
There have been numerous advances in gene therapy and oncolytic virotherapy in recent years, especially with respect to cutting-edge animal models to test these novel therapeutics. With all of these advances, it is important to understand the biosafe
Externí odkaz:
https://doaj.org/article/f76a5b134f8345fc81f8e1e8a77b38a9
Autor:
Ariella M. Altman MD, McKenzie J. White MD, Schelomo Marmor PhD, MPH, Dip Shukla MD, Katherine Chang MD, Emil Lou MD, Christopher J. LaRocca MD, Jane Y.C. Hui MD, MS, Todd M. Tuttle MD, MS, Eric H. Jensen MD, Jason W. Denbo MD
Publikováno v:
Cancer Control, Vol 29 (2022)
Background It is unclear whether the addition of chemoradiation (CRT) to adjuvant chemotherapy (CT) following upfront resection of pancreatic ductal adenocarcinoma (PDAC) provides any benefit. While some studies have suggested a benefit to combined m
Externí odkaz:
https://doaj.org/article/4ce64fca9933462bb2e01bf41701afe6
Autor:
Matthew Glen Robertson, Benjamin Bruce Eidenschink, Eriko Iguchi, Stanislav O. Zakharkin, Christopher J. LaRocca, Ezequiel J. Tolosa, Mark J. Truty, Kari Jacobsen, Martin E. Fernandez-Zapico, Julia Davydova
Publikováno v:
Molecular Therapy: Oncolytics, Vol 20, Iss , Pp 659-668 (2021)
Encoding the sodium iodide symporter (NIS) by an adenovirus (Ad) is a promising strategy to facilitate non-invasive imaging and radiotherapy of pancreatic cancer. However, insufficient levels of NIS expression in tumor cells have limited its clinical
Externí odkaz:
https://doaj.org/article/a978dc28a1fd4f84b44bea3c49ac95a1
Autor:
Christopher J. LaRocca, Stacey Wilber, Eric Jensen, Subree Subramanian, Clifford Steer, Julia Davydova
Publikováno v:
Journal of Clinical and Translational Science, Vol 7, Pp 128-128 (2023)
OBJECTIVES/GOALS: Colorectal cancer (CRC) is a leading cause of cancer mortality, and many patients will develop metastatic disease at some point during their treatment course. Conventional therapies such as surgery, chemotherapy, and radiation are o
Externí odkaz:
https://doaj.org/article/7f071ae114244c4aaafacbd8ccb4af58
Autor:
Saranya Prathibha, Anders D. Westanmo, Jane Yuet Ching Hui, Katie Westanmo, Amy A. Gravely, Todd M. Tuttle, Christopher J. LaRocca
Publikováno v:
Medicines, Vol 10, Iss 1, p 1 (2022)
Background: The proportion of women Veterans are increasing and, as such, access to high-quality breast cancer care is important. Prior studies have shown that rural location, age, and a mental health diagnosis negatively impact breast cancer screeni
Externí odkaz:
https://doaj.org/article/b0bdfb797767422c922bb6e14e06936c
Publikováno v:
Molecular Therapy: Oncolytics, Vol 13, Iss , Pp 93-106 (2019)
Cancer immunotherapy and the emergence of immune checkpoint inhibitors have markedly changed the treatment paradigm for many cancers. They function to disrupt cancer cell evasion of the immune response and activate sustained anti-tumor immunity. Onco
Externí odkaz:
https://doaj.org/article/d33d49ee949345dca50945b79a95b869
Autor:
McKenzie J. White, Madison Kolbow, Saranya Prathibha, Corinne Praska, Jacob S. Ankeny, Christopher J. LaRocca, Eric H. Jensen, Todd M. Tuttle, Jane Y. C. Hui, Schelomo Marmor
Publikováno v:
Breast Cancer Research and Treatment. 198:309-319
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1a49713bb119e85aab89fd59870da34d
https://doi.org/10.1007/s10549-023-06862-x
https://doi.org/10.1007/s10549-023-06862-x
Publikováno v:
Clinical and Translational Medicine, Vol 7, Iss 1, Pp 1-13 (2018)
Abstract Advances in the understanding of cancer immunotherapy and the development of multiple checkpoint inhibitors have dramatically changed the current landscape of cancer treatment. Recent large-scale phase III trials (e.g. PHOCUS, OPTiM) are est
Externí odkaz:
https://doaj.org/article/717c01ba82214ce3a3f50568703fc7c3